acarbose do not have cv risk reduction; insulin is not preferred before glp‑1 ra for ascvd risk mitigation." M

Instant feedback + full explanation. One question, done properly.

Hard"ADA Standards recommend a GLP‑1 RA with proven CV benefit for ASCVD; SGLT2 inhibitor is also appropriateType 2 Diabetesacarbose do not have cv risk reduction; insulin is not preferred before glp‑1 ra for ascvd risk mitigation."

A 52-year-old with type 2 diabetes (A1c 8.2%), eGFR 58 mL/min/1.73 m². On metformin. Next best glucose-lowering agent to reduce CV risk per ADA 2025?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

acarbose do not have cv risk reduction; insulin is not preferred befor